Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.36 |
| ▸ | CTSC | P53634 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 7/20 | 0.34 |
| ▸ | CTSK | P43235 | 6/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | CTSB | P07858 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23851119 | 0.82 | APLNR (0.34) | CTSSCTSCCTSK | |
| SCHEMBL1935295 | 0.79 | — | — | |
| SCHEMBL3831093 | 0.75 | CTSL (0.45) | CTSSCTSCCTSLCTSKCTSB | |
| SCHEMBL23573464 | 0.75 | CTSL (0.41) | CTSSCTSCCTSLCTSKCTSB | |
| SCHEMBL62133 | 0.74 | CTSS (0.49) | CTSSCTSLCTSKCTSB | |
| SCHEMBL19995774 | 0.74 | CTSC (0.38) | CTSSCTSCCTSLCTSKCTSB | |
| SCHEMBL24767282 | 0.71 | CTSS (0.36) | CTSSCTSCCTSLCTSKCTSB | |
| SCHEMBL5125202 | 0.71 | CNR1 (0.41) | CTSSCTSCCTSLCTSKDPP4 | |
| SCHEMBL14842066 | 0.71 | CTSL (0.36) | CTSSCTSCCTSLCTSKCTSB | |
| SCHEMBL15968247 | 0.69 | CTSS (0.43) | CTSSCTSCCTSLCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CTSS 3030/4885CTSC 1944/4885CTSL 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.